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646a Wednesday, February 19, 2014experimental system has a broad range of application possibilities for unveiling
single sarcomere dynamics during excitation-contraction coupling in cardio-
myocytes in the beating heart in vivo. At the meeting, we will discuss the or-
ganization of sarcomeric contraction in the beating heart in vivo.
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End Systolic Strain Rate, not Afterload, Controls Myocardial Relaxation
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Classical ex vivo experiments suggest that the relaxation of cardiac muscle de-
pends on afterload, with lower afterloads producing faster relaxation (Brutseart
et al Circ Res 1980 47(5):637). These original experiments used protocols in
which the muscle returned to its original length before beginning diastolic
relaxation (black lines, Figure 1). In this experimental mode, reducing afterload
increases the velocity of the muscle when
as returns to its original length (the end
systolic strain rate). In this work, we used
electrically simulated rat trabeculae to
test the hypothesis that the strain rate,
and not the afterload, controls relaxation.
We varied the end-systolic strain rate by
allowing the trabeculae to relengthen by
different amounts at a fixed afterload.
Relaxation was slowest when relengthen-
ing was minimal (gray lines, Figure 1)
and fastest when relengthening was com-
plete (black lines, Figure 1). Preload did
not influence this effect. In summary, our
preliminary data suggest that is the strain
rate at the end of systole, and not the force
that the myocardium develops as it con-
tracts, that controls relaxation.3264-Plat
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Background. Experimentally upregulating compliant titins has been suggested
as a possible therapeutic for lowering pathological diastolic stiffness levels.
However, how increasing titin compliance impacts global cardiac function re-
quires in-depth study.Here we investigate the effect of upregulating compliant
titins on diastolic and systolic function in a novel mouse model that we made
with a genetically altered titin splicing factor. We employed integrative ap-
proaches from intact cardiomyocytes studied with a carbon-fiber force-
measuring system to the left ventricular (LV) chamber studied with
pressure(P)-volume(V) analysis and Doppler echocardiography.
Methods and Results. Compliant titins were upregulated through deletion of
the RNA Recognition Motif of the splicing factor RBM20(Rbm20DRRMmice).
At both cardiomyocyte and LV chamber levels diastolic stiffness was reduced
in heterozygous (þ/-) Rbm20DRRMmice with a further reduction in homozygous
(-/-) mice at only the intact myocyte level. Fibrosis was present in only -/-
Rbm20DRRM hearts. The Frank-Starling Mechanism was reduced in a graded
fashion in Rbm20DRRM mice, at both the cardiomyocyte and LV chamber lev-
els.Exercise tests revealed an increase in exercise capacity in þ/- mice.
Conclusions. Results support that titin is not only important in diastolic but
also in systolic cardiac function. Upregulating compliant titin isoforms reduces
diastolic chamber stiffness due to increased compliance of myocytes but de-
presses systolic cardiac reserve; under conditions of exercise-induced cardiac
stress the beneficial effects on diastolic function dominate. Therapeutic manip-
ulation of the RBM20-based splicing system and careful dosing might be able
to avoid effects on fibrosis and systolic function while improving diastolic
function of heart failure patients.
Platform: Structure, Dynamics, and Allostery in
Drug Target Interactions
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Chemistry, University of Michigan, Ann Arbor, MI, USA.Structure-based docking has become a commonly used method for ligand dis-
covery and refinement, especially with the increased availability of high-
resolution structural data. Traditionally, these methods represent protein targets
as rigid receptors but proteins are fluid molecules that exist in an inter-
converting ensemble of conformational states. Recently, docking protocols
have trended towards incorporating protein flexibility but effectively and effi-
ciently searching the conformational space available to proteins remains a well-
appreciated computational challenge. To this end, we have developed a method
utilizing CHARMM to incorporate side
chain flexibility within grid-based dock-
ing methods, maintaining efficiency while
allowing the protein and ligand conforma-
tions to be sampled simultaneously. This
is unlike induced-fit docking methods
that search only one conformational
space, either protein or ligand, at a time.
Presented here are results for re-docking
and cross-docking simulations and an
assessment of the benefits of incorpo-
rating flexibility in docking when
compared to traditional rigid methods.
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Cyclic adenosine monophosphate (cAMP)-Protein Kinase A (PKA) signaling
is a fundamental pathway for mediating cellular responses to hormonal stim-
uli. cAMP activates PKA by binding to its regulatory (RIa) subunit. While
steps in the activation phase are well understood, little is known on how
signal desensitization/resetting occurs. We specifically set out to determine
(i) how cAMP-bound to the regulatory subunit is hydrolyzed to return RIa
to the kinase-bound state and (ii) the role of phosphodiesterases in enabling
this important regulatory resetting of the system. We report discovery of a
novel signaling complex of a phosphodiesterase (PDE8) and PKA Regulatory
subunit (RIa) in mammalian cAMP signaling by a combination of amide
hydrogen/deuterium exchange mass spectrometry (HDXMS), peptide arrays
and computational docking. A model of the PDE8A-PKA RIa complex re-
veals the phosphodiesterase active site in close proximity to the cAMP bind-
ing site on the PKA target and highlights a role for substrate channeling in
the PDE-dependent dissociation and hydrolysis of cAMP bound to PKA.
This is the first instance of PDEs directly interacting with a cAMP-
receptor protein in a mammalian system and highlights an entirely new class
of binding partners for RIa. This has major implications for regulation of in-
tensity and duration of the cAMP signal in all cells. Furthermore, this intro-
duces molecular channeling as a new paradigm for macromolecular
assemblies in microdomains and localized stimulus-response cycles in cell
signaling. Our model for molecular channeling are consistent with Fluores-
cence Resonance Energy Transfer- reporter assays for cAMP in cells,
providing a new model for understanding spatial and temporal regulation
of cAMP signaling.
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Human SIRT1, the most studied member of the mammalian family of seven
NADþ-dependent sirtuins, is composed of 747 amino acids with a catalytic
core and extended N- and C-terminal regions. Herein we report the design
and characterization of a human SIRT1 construct (mini-hSIRT1) containing
the minimal structural elements required for lysine deacetylation and cata-
lytic activation by sirtuin-activating compounds (STACs). Crystal structures
of mini-hSIRT1/STAC complexes define the STAC binding site within the
N-terminal domain, revealing key intra-molecular interactions. Site-
directed mutagenesis of full-length human SIRT1 confirmed the importance
of key residues in the STAC-binding domain. This structural information,
together with proton-deuteron exchange mass spectrometry data, suggests
a possible mechanism of STAC-mediated catalytic activation. The definitive
determination of the interface governing the binding of STACs with human
SIRT1 facilitates greater understanding of STAC activation of this enzyme
which holds significant promise as a therapeutic target for multiple human
diseases.
